Kesimpta (Ofatumumab) 20mg/0.4mL China | Anti-CD20 | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Kesimpta (China-Mainland)
Kesimpta (全欣达, ofatumumab) is the China-Mainland brand of ofatumumab, a fully human anti-CD20 monoclonal antibody developed by Novartis for the treatment of relapsing multiple sclerosis (MS). It is supplied as a 20 mg/0.4 mL solution for subcutaneous injection in a pre-filled autoinjector pen. Ofatumumab is administered as a once-monthly self-injection, which distinguishes it from the intravenous ofatumumab formulation used in other disease areas. In China, Kesimpta is approved for adult patients with relapsing forms of multiple sclerosis, and it is listed as a category B medicine in the national medical insurance drug list.
What Is Ofatumumab Used For?
Ofatumumab (Kesimpta) is used to treat relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis. Multiple sclerosis is a chronic autoimmune disease of the central nervous system in which the immune system attacks the protective myelin sheath around nerve fibres. As a once-monthly at-home injection, Kesimpta offers patients a convenient, high-efficacy disease-modifying therapy for reducing relapses and slowing disability progression.
How Does Ofatumumab Work?
Ofatumumab is a fully human monoclonal antibody that binds to CD20, a cell-surface antigen expressed on pre-B and mature B lymphocytes. By binding to CD20, ofatumumab triggers antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, depleting B cells from the circulation. Because B cells play a central role in the autoimmune attack on myelin that drives multiple sclerosis, reducing their numbers helps dampen the inflammatory process underlying relapses and disease activity.
Indications
In China-Mainland, Kesimpta (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis. It is the only high-efficacy biologic disease-modifying therapy approved in China for multiple sclerosis, which is listed in China's first catalogue of rare diseases.
Dosage
The recommended dose of Kesimpta is 20 mg by subcutaneous injection at weeks 0, 1 and 2 as the initial loading doses, followed by 20 mg once monthly starting at week 4. The medicine is given by subcutaneous injection into the abdomen, thigh or outer upper arm, and can be self-administered after training by a healthcare professional. The first injection should be performed under the supervision of a trained healthcare provider. The pre-filled autoinjector pen is for single use only and should be discarded after use.
Side Effects
The most common adverse reactions to ofatumumab include upper respiratory tract infection, systemic injection-related reactions, headache and local injection-site reactions. Injection-related reactions — such as fever, headache, muscle pain, chills and fatigue — occur most often within 24 hours of the first injection and are usually mild to moderate. A reduction in blood immunoglobulin M (IgM) levels has been observed, and patients should be monitored for signs of infection. Vaccination with live or live-attenuated vaccines should be completed before starting treatment.
Storage
Kesimpta should be stored under refrigeration at 2°C to 8°C, protected from light, in the original carton, and must not be frozen. The pre-filled autoinjector pen is for single use only. The medicine should be kept out of the reach of children and used before the expiry date printed on the packaging.
Why Choose the China Version of Kesimpta?
The China-Mainland Kesimpta is the locally registered, NMPA-approved presentation of ofatumumab, and the only high-efficacy biologic disease-modifying therapy for multiple sclerosis in China, reimbursed as a category B medicine under the national medical insurance. For patients and institutions seeking a reliable once-monthly anti-CD20 therapy, sourcing through GLT adds verification of authenticity, cold-chain integrity and the complete export documentation needed for cross-border procurement, keeping the process transparent and traceable.
How to Order
To source China-Mainland Kesimpta (ofatumumab) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the quantity and your destination, and we will confirm current stock, cold-chain logistics and the import documentation required. A valid prescription is required, and we serve both institutions and individual patients.
FAQ
What is the Chinese brand name of Kesimpta? In China, Kesimpta (ofatumumab) is known as 全欣达 and is marketed by Novartis.
Is ofatumumab covered by medical insurance in China? Yes. Ofatumumab (Kesimpta) is listed as a category B medicine in China's national medical insurance drug list.
What is Kesimpta used to treat? Kesimpta treats relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS.
How is Kesimpta given? It is given by subcutaneous injection at weeks 0, 1 and 2, then once monthly, using a pre-filled autoinjector pen that can be self-administered after training.
Is Kesimpta the same as intravenous ofatumumab? Kesimpta is a subcutaneous, once-monthly formulation of ofatumumab for multiple sclerosis, whereas intravenous ofatumumab is used in other disease areas. They share the same active ingredient but differ in route and indication.